Compagnie Lombard Odier SCmA’s Dyne Therapeutics DYN Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-18,000	Closed	-$228K	–	431
2025 Q3	$228K	Hold	18,000	–	–	﹤0.01%	245
2025 Q2	$171K	Buy	18,000 +11,000	+157%	+$121K	﹤0.01%	252
2025 Q1	$73.2K	Hold	7,000	–	–	﹤0.01%	330
2024 Q4	$165K	Hold	7,000	–	–	﹤0.01%	257
2024 Q3	$251K	Hold	7,000	–	–	﹤0.01%	222
2024 Q2	$247K	Buy	+7,000	New	+$203K	﹤0.01%	224

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Compagnie Lombard Odier SCmA's DYN Position: Q4 2025 in Review

Compagnie Lombard Odier SCmA sold out of Dyne Therapeutics (DYN) in Q4 2025, closing a stake of 18,000 shares — an estimated $228K sold.

Compagnie Lombard Odier SCmA first reported a position in DYN in Q2 2024 and held it in 6 quarters. The position peaked at $251K in Q3 2024. 232 funds tracked by Wall St. Rank hold DYN as of Q4 2025.

Compagnie Lombard Odier SCmA reported no remaining Dyne Therapeutics position as of Q4 2025 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 18,000 Dyne Therapeutics shares in Q4 2025, an estimated $228K.
Compagnie Lombard Odier SCmA first reported a position in Dyne Therapeutics in Q2 2024 and held it in 6 quarters.
Compagnie Lombard Odier SCmA's Dyne Therapeutics position peaked at $251K in Q3 2024.
232 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2025.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2025, filed 16 Jan 2026.